Compositions and methods for inducing immune tolerance
First Claim
1. A method for reducing antigen-specific antibodies to a polypeptide antigen in a subject, comprising administering to the subject a pharmaceutical composition comprising a liposome;
- a CD22, Siglec G, or Siglec-10 glycan ligand; and
an effective amount of a T cell-dependent MHC class II, B cell-specific polypeptide antigen that is linked to a lipid and co-displayed on the liposome with the CD22, Siglec G, or Siglec-10 glycan ligand;
to thereby reduce production of antibodies to the antigen by B cells in the subject.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec)expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition that co-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.
-
Citations
7 Claims
-
1. A method for reducing antigen-specific antibodies to a polypeptide antigen in a subject, comprising administering to the subject a pharmaceutical composition comprising a liposome;
- a CD22, Siglec G, or Siglec-10 glycan ligand; and
an effective amount of a T cell-dependent MHC class II, B cell-specific polypeptide antigen that is linked to a lipid and co-displayed on the liposome with the CD22, Siglec G, or Siglec-10 glycan ligand;
to thereby reduce production of antibodies to the antigen by B cells in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- a CD22, Siglec G, or Siglec-10 glycan ligand; and
Specification